IPM Pulse: Growth recovers from weak Dec
* SUNP, CIPLA, TRP, IPCA and DRRD
outperform: Based on Jan’24 MAT IPM data, Sun retained its top spot with ~8% market share (ms). For the same period, JB Pharma has improved its rank by 2 places to 22nd . For the month of Jan ’24, from our coverage, IPCA, Cipla, SUNP, TRP and DRRD outperformed the IPM, growing 14.3%/9.6%/8.9%/8.6%/8.3% YoY respectively. ZYDUSLIF and LPC underperformed the IPM due to mixed performance of top brands for...
Sector Update : IPM Pulse: Growth recovers from weak Dec By JM Financial Institutional Securities
In 3QFY24, we expect double-digit domestic growth from IPCA, TRP, CIPLA and SUNP. We expect gRevlimid contribution of USD 95mn/ USD 54mn/ USD 20mn for DRRD, Cipla and SUNP, respectively. SUNP (specialty growth, gRevlimid, Mohali supply resumption) and LPC (gSpiriva, gPrezista) can potentially deliver positive earnings surprise. We expect sequential improvement in BIOS’ revenue driven by ramp-up in existing biosimilars, higher generics revenue and research contribution. Due to Unichem ac...
Healthcare Sector Update : 3QFY24 Preview: US growth to sustain, domestic steady By JM Financial Institutional Securities Ltd
